Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis
M. S. Espindola, D. M. Habiel, A. L. Coelho, A. Mikels-Vigdal, C. M. Hogaboam
This study examines the role of LOXL2 in IPF using Simtuzumab, finding it enhances myofibroblast differentiation and fibrosis but shows no therapeutic efficacy.
bioRxiv · Oct 22, 2019Cell Biology